Recently, CMS has been successfully selected as a constituent stock of the Hong Kong Exchanges and Clearing Tech 100 Index (“HKEX Tech 100”). As the first Hong Kong stock index launched by HKEX, it aims to track the performance of the 100 largest-cap Hong Kong-listed companies that are highly relevant to the technology theme and eligible for the?Southbound Stock Connect, covering six cutting-edge sectors including artificial intelligence, biotechnology and pharmaceuticals, electric vehicles and intelligent driving. Its launch responds to the diversified investment demands of the capital market for the technology sector, providing investors with an efficient tool to allocate assets in leading Hong Kong-listed technology companies. This inclusion fully reflects the capital market’s recognition of CMS’s innovative development strength and investment prospects.
CMS is firmly advancing its three core strategies of product innovation, commercial model?reform and international expansion, and is gradually achieving the strategic transition to a “specialty-focused, innovation-excellent international pharmaceutical enterprise”. Among these, “innovation-driven” takes top priority in the three strategies. Through the dual-engine model of “collaborative development and?in-house?R&D”, the Group focuses on its advantageous specialty areas including cardio-cerebrovascular, central nervous system, gastroenterology, ophthalmology and skin health, building an innovative product pipeline centered on potential first-in-class (FIC) and best-in-class (BIC) products, and efficiently advancing clinical development and commercialization to provide more quality pharmaceutical solutions for patients.
As of now, CMS has a portfolio of differentiated innovative products, with 5 products in the commercialization phase, 7 products under marketing approval review, and more than 10 products in clinical development.
While consolidating its innovation core, CMS continues to promote commercial model?reform and international expansion, forging the enterprise’s anti-cyclical resilience with forward-looking strategies. The Group actively deploys?new retail and new media channels?while strengthening its consumer healthcare portfolio. Dermavon, its subsidiary specialized in the skin health business, has submitted an application for a separate listing on the Main Board of the Stock Exchange of Hong Kong Limited, which will further unlock its high-growth potential. In addition, the Group has completed a secondary listing on the Singapore Exchange via introduction, which will help deepen its integrated R&D, manufacturing and commercialization operations in Southeast Asia and the Middle East, thereby?elevating?the internationalization of the pharmaceutical enterprise through the “industrial internationalization” path.
CMS will continue to consolidate its core competitiveness, striving?to become a benchmark enterprise in the capital market with both value attributes?and high-growth potential, and create long-term and stable returns for investors.
CMS Disclaimer and Forward-Looking Statements
This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.
This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.